Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Robinson

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency VirusSarah Fidler, Julie Fox, Timothy Tipoe, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Journal of Medical Genetics|March 2, 2022
Consolidation of the clinical and genetic definition of a <i>SOX4-</i>related neurodevelopmental syndromeMarco Angelozzi, Anirudha Karvande, Arnaud N Molin, et al.
Nature Medicine|May 7, 2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency VirusSarah Fidler, Julie Fox, Timothy Tipoe, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
Journal of Medical Genetics|March 2, 2022
Consolidation of the clinical and genetic definition of a <i>SOX4-</i>related neurodevelopmental syndromeMarco Angelozzi, Anirudha Karvande, Arnaud N Molin, et al.
Nature Medicine|May 7, 2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
The Lancet. HIV|June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialJohn Frater, Katie J Ewer, Ane Ogbe, et al.
Pageof 11